# Study of 2LHERP® in Genital Herpes Infections

> **NCT04235322** · PHASE4 · TERMINATED · sponsor: **Labo'Life** · enrollment: 6 (actual)

## Conditions studied

- Herpes Simplex, Genital

## Interventions

- **DRUG:** 2LHERP®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04235322
- **Lead sponsor:** Labo'Life
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-25
- **Primary completion:** 2023-04-18
- **Final completion:** 2023-04-18
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Labo'life decided to end prematurely HEARTH-GEN study from April 18th 2023 due to very low recruitment rates (6/100). Labo'life decided to focus all its efforts on another study using 2LHERP® in herpes treatment, called HEARTH-OF (NCT04065971)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04235322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04235322, "Study of 2LHERP® in Genital Herpes Infections". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04235322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*